Contineum Therapeutics, Inc. (CTNM)
NASDAQ · Healthcare
Contineum Therapeutics, Inc. Shareholder Equity 2023–2024
Contineum Therapeutics, Inc. annual/quarterly shareholder equity history from 2023 to 2024. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Contineum Therapeutics, Inc. shareholder equity for the quarter ending December 31, 2024 were 198.1M, a 391.55% decrease year-over-year.
- Contineum Therapeutics, Inc. shareholder equity for 2024 were 198.1M, a 391.55% decrease from 2023.
- Contineum Therapeutics, Inc. shareholder equity for 2023 were -67.9M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Contineum Therapeutics, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2024 | $198 |
| 2023 | $-68 |
| Contineum Therapeutics, Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2024-12-31 | $198 |
| 2023-12-31 | $-68 |
Contineum Therapeutics, Inc. Shareholder Equity — FAQ
Contineum Therapeutics, Inc. (CTNM) shareholder equity over the last 2 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CTNM's shareholder equity history?
The chart and table above show Contineum Therapeutics, Inc.'s shareholder equity by year and by quarter, including the growth rate.